Edwards Lifesciences Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.0%projected annual EPS growth
Analyst Coverage
26analysts covering
FY Revenue (est.)
$6.8Bnext fiscal year
FY EPS (est.)
$3.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Transcatheter Aortic Valve Replacement (TAVR) Sales Growth Quarterly10.5%Target: 8% to 9% full-year 2026 growth
Transcatheter Mitral and Tricuspid Therapies (TMTT) Sales Quarterly195.9MTarget: $760 million to $780 million full-year 2026
Adjusted Operating Profit Margin Quarterly30.0%Target: High end of 28% to 29% range for full-year 2026
Watch Items
- CMS National Coverage Determination for TAVRTrigger: September 2026 decisionAction: Monitor for potential expansion of TAVR coverage criteria which could accelerate procedure volumes.
- TMTT Mitral and Tricuspid Adoption and ScalingTrigger: Sustained 40%+ year-over-year growthAction: Track clinical adoption of PASCAL, EVOQUE, and SAPIEN M3 systems to validate the $2 billion revenue target by 2030.
Research as of 2 Sep 2026